DoD Peer Reviewed Alzheimer’s, Accelerating Diagnostics for Traumatic Brain Injury Research Award | W81XWH 20 PRARP ADTBI

Opportunity Information: Apply for W81XWH 20 PRARP ADTBI

The DoD Peer Reviewed Alzheimers, Accelerating Diagnostics for Traumatic Brain Injury Research Award (FY20 PRARP ADTBI; Funding Opportunity Number W81XWH 20 PRARP ADTBI) is a Department of Defense research funding opportunity run through the U.S. Army Medical Research Acquisition Activity (USAMRAA). Its central aim is to speed the development of clinically useful diagnostic and/or prognostic biomarkers for chronic traumatic brain injury (TBI) specifically in ways that clarify, predict, or connect to Alzheimers disease and Alzheimers disease related dementias (AD/ADRD). The program is designed for work that is ready to move beyond early discovery and toward outputs that can be transferred to clinical practice relatively quickly, with an emphasis on real-world impact rather than exploratory science for its own sake.

A key feature of this opportunity is its focus on biomarker qualification rather than basic biomarker discovery. In this mechanism, biomarker qualification is treated as an evidence-building process: applicants are expected to show how a proposed biomarker is meaningfully linked to underlying biological processes and to clinically relevant endpoints. While projects may include biomarker validation activities, validation is framed as a supporting component that strengthens the larger qualification goal. Validation, as defined in the announcement, centers on measurement performance characteristics such as reproducibility, accuracy, precision, and sensitivity limits. If a proposal includes validation work, it needs to clearly explain how those technical performance assessments will advance the broader case that the biomarker is clinically interpretable and useful for chronic TBI in the context of AD/ADRD outcomes.

The announcement makes clear that the biomarker under study must be human-relevant and tied to clinical endpoints, with particular attention to cognition and/or behavior that matters to both TBI and AD/ADRD research. In other words, it is not enough to show that a marker changes after injury; the marker should connect to outcomes clinicians care about, such as cognitive performance, functional status, or other clinically meaningful behavioral measures that overlap the TBI and dementia space. The program also expects applicants to show that their biomarker approach could improve specificity and sensitivity for diagnosing and/or forecasting chronic TBI trajectories as they relate to later AD/ADRD, making performance and clinical interpretability a central part of the rationale.

Because the award is explicitly human-based and not intended for early discovery, animal research is prohibited. That restriction reinforces the program’s translational intent: it is meant to support studies grounded in human participants and human data that are positioned to qualify biomarkers for practical use. The opportunity encourages a range of diagnostic modalities, including fluid-based biomarkers (for example blood-based measures), imaging-based approaches, retinal assessments, and wearable device derived signals. This broad encouragement suggests the program is open to different technology pathways as long as they are tied to the core requirement: developing robust, clinically actionable markers for chronic TBI that inform AD/ADRD relevant endpoints.

Operational feasibility is treated as a major requirement rather than an afterthought. Applicants must either already have access to an existing cohort or provide a credible plan for expedited participant accrual, and they must explain why the cohort or participant population is suitable for the study aims. This means reviewers are expected to weigh whether the proposed work can actually be executed on the intended timeline with adequate sample access and appropriate participant characteristics, rather than being dependent on uncertain recruitment. Along the same lines, the principal investigator is expected to demonstrate that the study team has experience spanning both TBI research and AD/ADRD research, reflecting the interdisciplinary nature of the scientific question and the need for credible expertise across both areas.

Finally, the program stresses impact-based applications. Proposals should clearly articulate near-term outcomes that can be attributed directly to the proposed research, such as a biomarker moving closer to qualification or demonstrating a clear link to clinical endpoints, as well as longer-term scientific gains, such as establishing a foundation for broader clinical adoption or shaping future diagnostic standards. Administrative details included in the source information indicate it is a discretionary opportunity using grant and cooperative agreement instruments under CFDA 12.420, with unrestricted eligibility in principle (subject to any additional eligibility clarifications in the full announcement). The posting date was May 19, 2020, with an original closing date of July 21, 2020, and it anticipated a very limited number of awards (listed as one), underscoring that it is a highly competitive, focused mechanism aimed at a small number of high-impact projects.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Peer Reviewed Alzheimer’s, Accelerating Diagnostics for Traumatic Brain Injury Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on May 19, 2020.
• Applicants must submit their applications by Jul 21, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 20 PRARP ADTBI

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: